Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › PCR › Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Sep 25, 2020
|
staff reporter

NEW YORK— Biomarker test developer Biovica has filed a 501(k) submission with the US Food and Drug Administration for its DiviTum assay for monitoring breast cancer treatment response.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
17
Featured Webinar

Spatial Expression Analyses Elucidates Mechanisms of circRNAs in Cancer

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.